Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

Over the past year, Eli Lilly ($LLY) stock has tumbled almost 24%, pressured by regulatory concerns, disappointing trial ...

Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline. Click here to read more ...

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

Shares in Danish pharma company Novo Nordisk jumped after it halved the out-of-pocket price of Ozempic in the US and gained ...

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk's weight-loss treatment Wegovy gained U.S. approval to treat a progressive liver condition on Friday, as the Danish drugmaker looks to boost sales and widen insurance coverage. Eli ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...